Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer

Testosterone plays a significant role in maintaining the tumor microenvironment. The role of the target serum testosterone (TST) level in enzalutamide- (Enza) and abiraterone (Abi)-treated castration-resistant prostate cancer (CRPC) patients was studied. In total, 107 patients treated with Enza and/...

Full description

Bibliographic Details
Main Authors: Shinichi Sakamoto, Maihulan Maimaiti, Minhui Xu, Shuhei Kamada, Yasutaka Yamada, Hiroki Kitoh, Hiroaki Matsumoto, Nobuyoshi Takeuchi, Kosuke Higuchi, Haruhito A. Uchida, Akira Komiya, Maki Nagata, Hiroomi Nakatsu, Hideyasu Matsuyama, Koichiro Akakura, Tomohiko Ichikawa
Format: Article
Language:English
Published: MDPI AG 2019-04-01
Series:Journal of Clinical Medicine
Subjects:
abiraterone
enzalutamide
prostate cancer
androgen deprivation therapy
testosterone
castration resistant prostate cancer
Online Access:https://www.mdpi.com/2077-0383/8/4/489

Internet

https://www.mdpi.com/2077-0383/8/4/489

Similar Items